Tergus Pharma CEO and leadership

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to several successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace.

After earning his doctorate in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization.

Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to several successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace.

After earning his doctorate in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization.

Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to several successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace.

After earning his doctorate in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization.

Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.